Research programme: multiple myeloma therapeutic - BioNeviaAlternative Names: BNV-215
Latest Information Update: 04 Jul 2013
At a glance
- Originator Bionevia Pharmaceuticals
- Developer BioNevia Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 03 Jul 2013 Preclinical trials in Multiple myeloma in USA (unspecified route)
- 05 Jun 2013 Early research in Multiple myeloma in USA (unspecified route)